Ruconest Alternatives Compared
| Ruconest (conestat alfa) | Berinert (C1 esterase inhibitor (human)) | Takhzyro (lanadelumab) |
|
|---|
| Ruconest (conestat alfa) | Berinert (C1 esterase inhibitor (human)) | Takhzyro (lanadelumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ruconest is used to treat hereditary angioedema (HAE) in adults and adolescents and is given by slow intravenous injection over 5 minutes, usually by a healthcare professional. Headache, nausea, and... View more |
Prescription only
Berinert is used to treat hereditary angioedema (HAE) in adults and children and people can be taught how to self-administer it intravenously at home. An increase in the severity of pain associated... View more |
Prescription only
Takhzyro works by binding to a protein called kallikrein and inhibiting its activity and may be used to prevent hereditary angioedema (HAE) attacks in adults, adolescents, and children aged 2 years... View more |
||||||||||||||||||||||||
| More about Ruconest (conestat alfa) | More about Berinert (C1 esterase inhibitor (human)) | More about Takhzyro (lanadelumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Ruconest has an average rating of 10.0 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Berinert has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Takhzyro has an average rating of 9.7 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Ruconest prices |
View all Berinert prices |
View all Takhzyro prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other C1 esterase inhibitor (human) brands include: Cinryze, Haegarda |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
3 hours |
152 hours |
360 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 48 drugs are known to interact with Ruconest:
|
A total of 49 drugs are known to interact with Berinert:
|
A total of 2 drugs are known to interact with Takhzyro:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
August 23, 2018 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.